Compare Tesla, Inc. (TSLA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tesla, Inc. vs GeneDx Holdings Corp — how do they compare? Tesla, Inc. trades at $326.44 (market cap $1.31T), while GeneDx Holdings Corp trades at $81.63 (market cap $2.44B). The key difference: Tesla, Inc. is far larger — about 536.9× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| TSLA | WGS | |
|---|---|---|
Market Cap | $1.31T | $2.44B |
Sector | Consumer Cyclical | Technology |
52-Week High | $489.88 | $167.51 |
52-Week Low | $298.16 | $34.51 |
Enterprise Value | $1.29T | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tesla (TSLA) trades at $326.58, down 1.3% over the past 24 hours, with a bearish technical signal driven by moving averages. The stock shows elevated valuation ratios, including a P/E of 308.16 and P/S of 11.36, while recent earnings performance was mixed with a Q2 2026 miss. Cash flow trends indicate heavy capital expenditure, and revenue growth has slowed, with net income margin at 3.67% for 2025. Recent news highlights regulatory approval for driver-assistance software in Europe and discussions on Tesla's strategic pivot toward AI and robotics.
Tesla faces near-term headwinds from valuation concerns and competitive pressures, but long-term growth potential hinges on autonomous driving technology and energy segment expansion. Key risks include execution challenges in new business lines and macroeconomic sensitivity. Analyst consensus is mixed with a $393.87 price target, suggesting cautious optimism amid high volatility.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
